Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.
['Launay-Vacher|V|V|', 'Aapro|M|M|', 'De Castro|G|G|', 'Cohen|E|E|', 'Deray|G|G|', 'Dooley|M|M|', 'Humphreys|B|B|', 'Lichtman|S|S|', 'Rey|J|J|', 'Scotté|F|F|', 'Wildiers|H|H|', 'Sprangers|B|B|']
D000077548:Anaplastic Lymphoma Kinase D020533:Angiogenesis Inhibitors D000970:Antineoplastic Agents D066246:ErbB Receptors D006801:Humans D007674:Kidney Diseases D058990:Molecular Targeted Therapy D047428:Protein Kinase Inhibitors D048493:Proto-Oncogene Proteins B-raf D053245:RANK Ligand D020794:Receptor Protein-Tyrosine Kinases D018719:Receptor, ErbB-2 D040262:Receptors, Vascular Endothelial Growth Factor D058570:TOR Serine-Threonine Kinases
molecular targeted therapy cancer nephrotoxicity renal toxicity kidney disease renal failure